Study of Oral PQR309 in Patients With Advanced Solid Tumors
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Alex Adjei
Mayo Clinic
Principal Investigator - Andreas Wicki
Basel University Hospital
Principal Investigator - Filip Janku
MD Anderson Cancer
Principal Investigator - Jordi Rodon
Vall d'Hebron University Hospital
Principal Investigator - Martin Forster
University College London Hospitals
Principal Investigator - Mateusz Opyrchal
Roswell Park Cancer Institute
Study Director - Sarah Bladgen
Chruchill Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- M.D. Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 21 Mar 2019
- Primary completion
- 21 Mar 2019
- Completion
- 21 Mar 2019
- Last update posted
- 22 Mar 2019
- Registered enrollment
- 70
- Registry id
- NCT02483858
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.